TSH Biopharm Corp Ltd is a Taiwan-based company mainly engaged in the manufacture and sales of medications. The Company mainly provides cardiovascular medications, gastrointestinal medication, central nervous system medications, and precision medical testing, including Amtrel, Rhynorm, Mopride, Aleviatin, Lonine, and others. The Company also provides vaccine, health supplement and testing services. Sales channels include hospitals and open clinics. The Company mainly distributes its products in the domestic market.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-10-22	NT$54.70	-0.55%	61,710
26-10-21	NT$55.00	0.00%	29,166
26-10-20	NT$55.00	-0.72%	24,519
26-10-19	NT$55.40	-1.42%	62,919
26-10-16	NT$56.20	+2.74%	78,608

End-of-day quote Taipei Exchange

More quotes

End-of-day quote Taipei Exchange 2026-10-22			5-day change	1st Jan Change
54.70 ^TWD	-0.55%		-2.67%	-6.50%

08-04	TSH Biopharm Corporation Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-05	TSH Biopharm Corporation Limited Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	2.1B 64.44M 57.54M 53.16M 48.17M 90.13M 6.12B 91.62M 640M 253M 3.2B 242M 237M 10.1B	P/E 2024	20.9x	P/E 2025	16.2x
Enterprise Value	1.19B 36.41M 32.51M 30.03M 27.22M 50.92M 3.46B 51.76M 361M 143M 1.81B 137M 134M 5.71B	EV / Sales 2024	1.32x	EV / Sales 2025	1x
Free-Float	34.36%	Yield 2024	3.46%	Yield 2025	4.46%

08-04	TSH Biopharm Corporation Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-05	TSH Biopharm Corporation Limited Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-05	TSH Biopharm Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-04	TSH Biopharm Corporation Limited announces Annual dividend, payable on July 13, 2026	CI
12-08	Zhaoke Ophthalmology Limited Enters into Strategic Partnership with TSH Biopharm Corporation Limited	CI
11-05	TSH Biopharm Corporation Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-08-03	TSH Biopharm Corporation Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-05-07	TSH Biopharm Corporation Limited Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-02-23	TSH Biopharm Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-02-20	TSH Biopharm Corporation Limited announces Annual dividend, payable on July 11, 2025	CI
24-11-24	TSH Biopharm Corporation Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
24-08-12	TSH Biopharm Corporation Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
24-08-07	TSH Biopharm Corporation Limited Appoints Remuneration Committee	CI

22-08-09	TSH Biopharm : is invited to attend the online institutional investor conference hosted by IBF Securities	PU
22-08-04	TSH Biopharm : Board of Directors Approved Financial Statements For the Six Months Ended June 30, 2022	PU
22-08-04	TSH Biopharm : Announcement of setting up the Sustainable Development Committee and members of TSH's first Sustainable Development Committee	PU
22-05-24	TSH Biopharm : was invited to attend the online institutional investor conference hosted by Concord Securities	PU
22-05-24	TSH Biopharm : Announcement of Change to Remuneration Committee member	PU

TSH Biopharm Corporation Limited Stock

Stocks

8432

TW0008432006

Pharmaceuticals

Valuation: TSH Biopharm Corporation Limited

Chart: TSH Biopharm Corporation Limited

Latest news: TSH Biopharm Corporation Limited

Press Releases: TSH Biopharm Corporation Limited

Quotes and Performance

Price Extremes

Managers and Directors: TSH Biopharm Corporation Limited

Other Pharmaceuticals

Financials

Company Profile

Quotes

1 day	-0.55%
1 week	-2.67%
Current month	+7.89%
1 month	+8.96%
3 months	+7.25%
6 months	+7.05%
Current year	-6.50%

1 week	54.7	56
1 month	50	56.5
Current year	48.6	58.9
1 year	48.6	59.3
3 years	43	71.1
5 years	39	71.1
10 years	38.8	101.5

Manager	Title	Age	Since
Ssu Yuan Yang CEO	Chief Executive Officer	-	2019-01-16
Chen Ju Kan DFI	Director of Finance/CFO	-	2010-08-31
Shu Ping Huang ADM	Chief Administrative Officer	-	-

Director	Title	Age	Since
Kun Hung Lai BRD	Director/Board Member	-	2011-10-05
Chao I Chiang BRD	Director/Board Member	-	2016-06-22
Zhi Li Wang BRD	Director/Board Member	-	2017-06-14

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TSH BIOPHARM CORPORATION LIMITED	-0.55%	-2.67%	-0.18%	+20.35%	64.44M
ELI LILLY AND COMPANY	-2.54%	+1.31%	+54.27%	+114.96%	1,135B
JOHNSON & JOHNSON	-1.42%	+3.23%	+38.56%	+74.44%	635B
ABBVIE INC.	+0.16%	+0.08%	+25.29%	+95.23%	505B
ROCHE HOLDING AG	-0.31%	+3.09%	+44.14%	+64.80%	378B
MERCK & CO., INC.	-1.34%	-0.47%	+66.04%	+41.00%	358B
NOVARTIS AG	-0.68%	+2.65%	+22.98%	+50.39%	295B
ASTRAZENECA PLC	-1.20%	+3.04%	+2.33%	+22.86%	266B
AMGEN INC.	-1.79%	+1.57%	+50.56%	+59.08%	237B
GILEAD SCIENCES, INC.	-0.73%	-0.10%	+29.02%	+99.67%	193B
Average	-1.04%	+1.68%	+33.30%	+64.28%	400.37B
Weighted average by Cap.	-1.35%	+2.66%	+41.02%	+79.75%

	2024	2025
Net sales	1.12B 34.23M 30.57M 28.24M 25.59M 47.87M 3.25B 48.67M 340M 135M 1.7B 128M 126M 5.37B	1.34B 41M 36.62M 33.83M 30.65M 57.35M 3.89B 58.3M 407M 161M 2.04B 154M 151M 6.43B
Net income	113M 3.47M 3.1M 2.86M 2.59M 4.85M 329M 4.93M 34.44M 13.64M 173M 13.02M 12.74M 544M	139M 4.27M 3.82M 3.52M 3.19M 5.98M 406M 6.07M 42.41M 16.79M 212M 16.03M 15.69M 670M
Net Debt	-877M -26.9M -24.02M -22.19M -20.11M -37.63M -2.55B -38.25M -267M -106M -1.34B -101M -98.82M -4.22B	-914M -28.03M -25.03M -23.12M -20.95M -39.2M -2.66B -39.85M -278M -110M -1.39B -105M -103M -4.4B